Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hasbro, Inc. (HAS) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance

Hasbro, Inc.Trade
IDEXX Laboratories, Inc.Trade

Price performance (Past 24H)

Key statistics

Hasbro, Inc. vs IDEXX Laboratories, Inc. — how do they compare? Hasbro, Inc. trades at $88.77 (market cap $11.53B), while IDEXX Laboratories, Inc. trades at $563.81 (market cap $44.48B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.9× Hasbro, Inc.'s market cap, and Hasbro, Inc. pays a 3.44% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.

HASIDXX
Market Cap
$11.53B$44.48B
Sector
Consumer CyclicalHealth
52-Week High
$105.88$766.68
52-Week Low
$70.95$520.87
Enterprise Value
$13.80B$45.38B
Dividend Yield
3.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hasbro, Inc.

Hasbro (HAS) surged 8.87% to $88.78, driven by strong Q2 2026 earnings that beat estimates with $1.14 billion revenue (up 16% YoY) and raised full-year guidance. Technicals show bullish momentum near resistance at $85, while fundamentals reveal mixed signals: positive cash flow trends and robust Wizards segment growth contrast with negative net income margins and high debt levels. Analyst sentiment is optimistic, with a consensus price target of $104.75 and no sell ratings among 33 covered analysts.

The outlook is cautiously positive, with Magic: The Gathering fueling growth, but risks include elevated valuation multiples (P/E 25.6, EV/EBITDA 41.99) and persistent profitability challenges. Investors may see upside if execution continues, though leverage and margin pressures warrant monitoring.

IDEXX Laboratories, Inc.

IDEXX Laboratories trades at $552.46, down 2.64% today, with neutral technical signals but strong fundamental performance. The company maintains robust profitability with 24.63% net margins and has beaten earnings expectations for three consecutive quarters. Recent news highlights AI integration in medical devices and upcoming Q2 2026 results on August 4, 2026. The stock shows consistent revenue growth from $3.4B in 2022 to $4.3B in 2025.

Outlook remains positive given earnings momentum and analyst consensus, though elevated valuation ratios (P/E 41.49) pose risks. Key catalysts include Q2 earnings release and continued AI adoption in veterinary diagnostics. Primary risks involve competitive pressures and market volatility affecting premium valuations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Hasbro, Inc.

Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.

Read more on HAS

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX